LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 80

Search options

  1. Article ; Online: Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation.

    Salvatierra, Juan / Aomar-Millán, Ismael Francisco / Hernández-Quero, José

    The Lancet. Rheumatology

    2021  Volume 3, Issue 4, Page(s) e248

    Language English
    Publishing date 2021-03-08
    Publishing country England
    Document type Journal Article
    ISSN 2665-9913
    ISSN (online) 2665-9913
    DOI 10.1016/S2665-9913(21)00064-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.

    Aomar-Millán, Ismael Francisco / Salvatierra, Juan / Hernández-Quero, José

    Internal and emergency medicine

    2021  Volume 16, Issue 4, Page(s) 1105–1106

    MeSH term(s) Adrenal Cortex Hormones/therapeutic use ; Antibodies, Monoclonal, Humanized ; COVID-19/drug therapy ; Humans ; Interleukin 1 Receptor Antagonist Protein/therapeutic use ; Pneumonia/drug therapy ; Retrospective Studies ; SARS-CoV-2
    Chemical Substances Adrenal Cortex Hormones ; Antibodies, Monoclonal, Humanized ; Interleukin 1 Receptor Antagonist Protein ; tocilizumab (I031V2H011)
    Language English
    Publishing date 2021-03-10
    Publishing country Italy
    Document type Letter ; Comment
    ZDB-ID 2454173-4
    ISSN 1970-9366 ; 1828-0447
    ISSN (online) 1970-9366
    ISSN 1828-0447
    DOI 10.1007/s11739-021-02690-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: On lung ultrasound scoring for the early evaluation of patients with COVID-19 and dyspnea.

    Gil-Rodríguez, Jaime / Benavente-Fernández, Alberto / Guirao-Arrabal, Emilio / Hernández Quero, José

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias

    2022  Volume 34, Issue 4, Page(s) 327–328

    Title translation Acerca de la evaluación precoz mediante ecografía pulmonar de pacientes con disnea por COVID-19.
    MeSH term(s) COVID-19/diagnostic imaging ; Dyspnea/etiology ; Humans ; Lung/diagnostic imaging ; Ultrasonography
    Language Spanish
    Publishing date 2022-07-14
    Publishing country Spain
    Document type Journal Article
    ZDB-ID 2127173-2
    ISSN 2386-5857 ; 2386-5857
    ISSN (online) 2386-5857
    ISSN 2386-5857
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Erythema nodosum: An uncommon manifestation of Rickettsiosis.

    Peregrina-Rivas, José Antonio / Guirao-Arrabal, Emilio / Ramos-Pleguezuelos, Francisco Manuel / Hernández-Quero, José

    Enfermedades infecciosas y microbiologia clinica (English ed.)

    2022  Volume 40, Issue 3, Page(s) 151–152

    MeSH term(s) Erythema Nodosum/diagnosis ; Erythema Nodosum/etiology ; Humans ; Rickettsia Infections/complications ; Rickettsia Infections/diagnosis
    Language English
    Publishing date 2022-02-04
    Publishing country Spain
    Document type Case Reports ; Letter
    ISSN 2529-993X
    ISSN (online) 2529-993X
    DOI 10.1016/j.eimce.2021.01.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Erythema nodosum: An uncommon manifestation of Rickettsiosis.

    Peregrina-Rivas, José Antonio / Guirao-Arrabal, Emilio / Ramos-Pleguezuelos, Francisco Manuel / Hernández-Quero, José

    Enfermedades infecciosas y microbiologia clinica (English ed.)

    2021  

    Language Spanish
    Publishing date 2021-02-20
    Publishing country Spain
    Document type Case Reports
    ISSN 2529-993X
    ISSN (online) 2529-993X
    DOI 10.1016/j.eimc.2021.01.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Ruminococcus gnavus bacteremia: Literature review and a case report associated with acute flare of ulcerative colitis in an immunocompromised patient.

    Martínez de Victoria Carazo, Javier / Vinuesa García, David / Serrano-Conde Sánchez, Esther / Peregrina Rivas, José Antonio / Ruíz Rodríguez, Antonio José / Hernández Quero, José

    Anaerobe

    2023  Volume 82, Page(s) 102762

    Abstract: We present a case of bacteremia caused by Ruminococcus gnavus in an immunocompromised patient. R. gnavus is a Gram-positive strict anaerobe bacterium that forms chains. The bacteremia has been associated with an acute flare of ulcerative colitis. ... ...

    Abstract We present a case of bacteremia caused by Ruminococcus gnavus in an immunocompromised patient. R. gnavus is a Gram-positive strict anaerobe bacterium that forms chains. The bacteremia has been associated with an acute flare of ulcerative colitis. Anaerobic bacteremia is becoming increasingly frequent in patients with compromised gastrointestinal barrier. The role of the human microbiota and its alterations in the pathogenesis of immune-related diseases is an expanding area of interest. R. gnavus has been identified as a microorganism that may be responsible for the development of these diseases. The contribution of anaerobic bacteria to the pathogenesis of inflammatory bowel disease (IBD) is discussed, and cases reported up until 2023 were reviewed.
    MeSH term(s) Humans ; Bacteremia/diagnosis ; Bacteremia/microbiology ; Colitis, Ulcerative/complications ; Colitis, Ulcerative/diagnosis ; Immunocompromised Host ; Ruminococcus
    Language English
    Publishing date 2023-07-21
    Publishing country England
    Document type Case Reports ; Review
    ZDB-ID 1237621-8
    ISSN 1095-8274 ; 1075-9964
    ISSN (online) 1095-8274
    ISSN 1075-9964
    DOI 10.1016/j.anaerobe.2023.102762
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Empirical treatment with doxycycline of fever of intermediate duration.

    Guirao-Arrabal, Emilio / Muñoz-Medina, Leopoldo / Anguita-Santos, Francisco / Vinuesa-García, David / Hernández-Quero, José

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

    2021  Volume 40, Issue 9, Page(s) 2047–2050

    MeSH term(s) Anti-Bacterial Agents/therapeutic use ; Communicable Diseases/diagnosis ; Communicable Diseases/drug therapy ; Communicable Diseases/pathology ; Doxycycline/therapeutic use ; Fever/drug therapy ; Fever/pathology ; Humans
    Chemical Substances Anti-Bacterial Agents ; Doxycycline (N12000U13O)
    Language English
    Publishing date 2021-07-30
    Publishing country Germany
    Document type Letter
    ZDB-ID 603155-9
    ISSN 1435-4373 ; 0934-9723 ; 0722-2211
    ISSN (online) 1435-4373
    ISSN 0934-9723 ; 0722-2211
    DOI 10.1007/s10096-021-04322-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada.

    Aomar-Millán, Ismael Francisco / Salvatierra, Juan / Torres-Parejo, Úrsula / Nuñez-Nuñez, María / Hernández-Quero, José / Anguita-Santos, Francisco

    Medicina clinica

    2021  Volume 156, Issue 12, Page(s) 602–605

    Abstract: Aim: To assess clinical outcomes according to the immunosuppressive treatment administered to patients with severe SARS-CoV-2 pneumonia and moderate inflammation.: Methods: A retrospective observational cohort study involving 142 patients with severe ...

    Title translation Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation.
    Abstract Aim: To assess clinical outcomes according to the immunosuppressive treatment administered to patients with severe SARS-CoV-2 pneumonia and moderate inflammation.
    Methods: A retrospective observational cohort study involving 142 patients with severe COVID-19 pneumonia and moderate inflammation divided into three treatment groups (pulses of methylprednisolone alone [groupI], tocilizumab alone [groupII] and methylprednisolone plus tocilizumab [groupIII]). The aim was to assess intergroups differences in the clinical course with a 60-day follow-up and related analytical factors.
    Results: 14 patients (9,8%) died: 8 (10%) in groupI and 6 (9,5%) in groupsII andIII. 15 (10,6%) were admitted to ICU: 2 (2,5%) from groupI, 4 (28,5%) from groupII and 9 (18,4%) from groupIII. The mean hospital stay was longer in groupII and clinical outcome was not associated with treatment.
    Conclusions: Tocilizumab seems to be not associated with better clinical outcomes and should be reserved for clinical trial scenario, since its widespread use may result in higher rate of ICU admission and longer mean hospital stay without differences in mortality rate and potentially adverse events.
    MeSH term(s) Antibodies, Monoclonal, Humanized ; COVID-19/drug therapy ; Glucocorticoids/therapeutic use ; Humans ; Inflammation ; Retrospective Studies ; SARS-CoV-2 ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal, Humanized ; Glucocorticoids ; tocilizumab (I031V2H011)
    Language Spanish
    Publishing date 2021-01-28
    Publishing country Spain
    Document type Case Reports ; Observational Study
    ZDB-ID 411607-0
    ISSN 1578-8989 ; 0025-7753
    ISSN (online) 1578-8989
    ISSN 0025-7753
    DOI 10.1016/j.medcli.2021.01.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation.

    Aomar-Millán, Ismael Francisco / Salvatierra, Juan / Torres-Parejo, Úrsula / Nuñez-Nuñez, María / Hernández-Quero, José / Anguita-Santos, Francisco

    Medicina clinica (English ed.)

    2021  Volume 156, Issue 12, Page(s) 602–605

    Abstract: Aim: To assess clinical outcomes according to the immunosuppressive treatment administered to patients with severe SARS-CoV-2 pneumonia and moderate inflammation.: Methods: A retrospective observational cohort study involving 142 patients with severe ...

    Abstract Aim: To assess clinical outcomes according to the immunosuppressive treatment administered to patients with severe SARS-CoV-2 pneumonia and moderate inflammation.
    Methods: A retrospective observational cohort study involving 142 patients with severe COVID-19 pneumonia and moderate inflammation divided into three treatment groups (pulses of methylprednisolone alone [group I], tocilizumab alone [group II] and methylprednisolone plus tocilizumab [group III]). The aim was to assess intergroups differences in the clinical course with a 60-day follow-up and related analytical factors.
    Results: 14 patients (9,8%) died: 8 (10%) in group I and 6 (9,5%) in groups II and III. 15 (10,6%) were admitted to ICU: 2 (2,5%) from group I, 4 (28,5%) from group II and 9 (18,4%) from group III. The mean hospital stay was longer in group II and clinical outcome was not associated with treatment.
    Conclusions: Tocilizumab seems to be not associated with better clinical outcomes and should be reserved for clinical trial scenario, since its widespread use may result in higher rate of ICU admission and longer mean hospital stay without differences in mortality rate and potentially adverse events.
    Language English
    Publishing date 2021-05-24
    Publishing country Spain
    Document type Case Reports
    ISSN 2387-0206
    ISSN (online) 2387-0206
    DOI 10.1016/j.medcle.2021.01.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Lung ultrasound score severity cut-off points in COVID-19 pneumonia. A systematic review and validating cohort.

    Gil-Rodríguez, Jaime / Martos-Ruiz, Michel / Benavente-Fernández, Alberto / Aranda-Laserna, Pablo / Montero-Alonso, Miguel Ángel / Peregrina-Rivas, José-Antonio / Fernández-Reyes, Daniel / Martínez de Victoria-Carazo, Javier / Guirao-Arrabal, Emilio / Hernández-Quero, José

    Medicina clinica (English ed.)

    2023  Volume 160, Issue 12, Page(s) 531–539

    Abstract: Objectives: Our purpose was to establish different cut-off points based on the lung ultrasound score (LUS) to classify COVID-19 pneumonia severity.: Methods: Initially, we conducted a systematic review among previously proposed LUS cut-off points. ... ...

    Abstract Objectives: Our purpose was to establish different cut-off points based on the lung ultrasound score (LUS) to classify COVID-19 pneumonia severity.
    Methods: Initially, we conducted a systematic review among previously proposed LUS cut-off points. Then, these results were validated by a single-centre prospective cohort study of adult patients with confirmed SARS-CoV-2 infection. Studied variables were poor outcome (ventilation support, intensive care unit admission or 28-days mortality) and 28-days mortality.
    Results: From 510 articles, 11 articles were included. Among the cut-off points proposed in the articles included, only the LUS > 15 cut-off point could be validated for its original endpoint, demonstrating also the strongest relation with poor outcome (odds ratio [OR] = 3.636, confidence interval [CI] 1.411-9.374). Regarding our cohort, 127 patients were admitted. In these patients, LUS was statistically associated with poor outcome (OR = 1.303, CI 1.137-1.493), and with 28-days mortality (OR = 1.024, CI 1.006-1.042). LUS > 15 showed the best diagnostic performance when choosing a single cut-off point in our cohort (area under the curve 0.650). LUS ≤ 7 showed high sensitivity to rule out poor outcome (0.89, CI 0.695-0.955), while LUS > 20 revealed high specificity to predict poor outcome (0.86, CI 0.776-0.917).
    Conclusions: LUS is a good predictor of poor outcome and 28-days mortality in COVID-19. LUS ≤ 7 cut-off point is associated with mild pneumonia, LUS 8-20 with moderate pneumonia and ≥20 with severe pneumonia. If a single cut-off point were used, LUS > 15 would be the point which better discriminates mild from severe disease.
    Language English
    Publishing date 2023-06-16
    Publishing country Spain
    Document type Journal Article
    ISSN 2387-0206
    ISSN (online) 2387-0206
    DOI 10.1016/j.medcle.2023.01.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top